10-Q: Dare Bioscience Reports Q3 2024 Results, Impacted by Royalty Sale and Ongoing Development

Dare Bioscience's Q3 2024 results show a net loss, but the company's year-to-date financials are positively impacted by a significant royalty sale, while the company continues to advance its women's health product pipeline.

Summary

• Dare Bioscience reported a net loss of $4.7 million for the third quarter of 2024, compared to a net loss of $8.3 million for the same period in 2023.
• However, for the nine months ended September 30, 2024, the company reported a net income of $1.5 million, a significant turnaround from the $25.1 million net loss in the same period of 2023.
• This positive shift is primarily due to a $20.4 million gain from the sale of future royalty and milestone rights to XOMA in April 2024.
• Operating expenses decreased significantly, with research and development expenses dropping from $6.7 million in Q3 2023 to $2.7 million in Q3 2024, and general and administrative expenses decreasing from $2.7 million to $2.0 million over the same period.
• The company's cash and cash equivalents stood at $11.2 million as of September 30, 2024, with a working capital of $1.8 million.
• The company has an accumulated deficit of approximately $169.8 million as of September 30, 2024.
• The company has ongoing obligations under various license and royalty agreements, with approximately $1.0 million in payments expected to upstream licensors in the fourth quarter of 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made significant progress in securing funding and advancing its pipeline, it also faces substantial financial challenges and risks. The positive impact of the royalty sale is balanced by the ongoing need for capital and the uncertainty of future success.

Positives

• The company achieved a net income of $1.5 million for the first nine months of 2024, a significant improvement from the previous year.
• The sale of royalty rights generated a substantial gain of $20.4 million, bolstering the company's financial position.
• Operating expenses, particularly research and development, have decreased significantly, indicating improved cost management.
• The company is actively progressing its key clinical programs, including Ovaprene and Sildenafil Cream.
• The company has secured substantial non-dilutive funding through grants from the Bill & Melinda Gates Foundation and ARPA-H.
• The company has established an equity line with Lincoln Park Capital for up to $15.0 million in financing.

Negatives

• The company reported a net loss of $4.7 million for the third quarter of 2024.
• The company has an accumulated deficit of approximately $169.8 million.
• The company's cash and cash equivalents are $11.2 million, which may not be sufficient to fund operations for the next 12 months.
• The company is dependent on raising additional capital to continue operations and development programs.
• The company is subject to ongoing obligations under various license and royalty agreements.
• The company received a notice from Nasdaq regarding non-compliance with the minimum Market Value of Listed Securities requirement.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of losses and the need for additional capital.
• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• The company is dependent on third-party collaborators, service providers, and suppliers.
• The company is subject to the risk of not achieving milestones under grant agreements, which could impact future funding.
• The company is subject to the risk of not regaining compliance with Nasdaq listing requirements, which could lead to delisting.
• The company is subject to the risk of dilution from sales of common stock under ATM offerings and the equity line arrangement.
• The company is subject to the risk of not achieving the Revenue Sharing Threshold with XOMA, which would mean no future income from XACIATO sales.

Future Outlook

The company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The company will focus its resources primarily on the advancement of Ovaprene and Sildenafil Cream, while also progressing the development of DARE-LARC1 and DARE-HPV with non-dilutive funding. The company expects to incur significant research and development expenses for at least the next twelve months.

Management Comments

• The company is focused on progressing the development of its existing portfolio of product candidates.
• The company is exploring opportunities to expand its portfolio by leveraging assets to which it holds rights or obtaining rights to new assets, with continued focus solely on women's health.
• The company will continue to evaluate and may pursue a variety of capital raising options on an on-going basis.

Industry Context

The company operates in the biopharmaceutical industry, specifically focusing on women's health. The company's focus on unmet needs in areas such as contraception, sexual health, and menopause aligns with broader industry trends towards personalized medicine and addressing specific patient populations. The company's reliance on strategic collaborations and licensing agreements is a common practice in the industry to leverage external expertise and resources.

Comparison to Industry Standards

• The company's reliance on non-dilutive funding through grants is a common strategy for early-stage biotech companies, similar to companies like Odonate Therapeutics and Agenus, which have also utilized grants to support their research and development efforts.
• The company's focus on women's health is similar to companies like Myovant Sciences and Agile Therapeutics, which also develop products in this area, but the specific product candidates and development strategies differ.
• The company's approach to licensing and collaboration agreements is similar to many other biotech companies, such as Arcus Biosciences and Blueprint Medicines, which have also used these strategies to advance their pipelines.
• The company's financial results, particularly the net loss and reliance on capital raises, are typical for a development-stage biotech company, similar to companies like Cassava Sciences and Amylyx Pharmaceuticals, which have also experienced significant losses while advancing their clinical programs.
• The company's sale of royalty rights is a strategy used by some biotech companies to generate non-dilutive capital, similar to companies like Ligand Pharmaceuticals, which have also monetized their royalty streams.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity offerings and the risk of loss if the company is unable to raise sufficient capital or achieve commercial success.
• Employees may be impacted by potential cost-cutting measures or changes in the company's strategic direction.
• Customers (potential patients) may benefit from the development of new treatment options for women's health conditions.
• Suppliers and creditors may be impacted by the company's financial condition and ability to meet its obligations.

Next Steps

• The company will continue to progress its pivotal Phase 3 clinical study of Ovaprene.
• The company will continue to advance Sildenafil Cream toward a Phase 3 clinical study.
• The company will continue to advance preclinical development of DARE-LARC1.
• The company will advance development of DARE-HPV toward a Phase 2 clinical study.
• The company will actively monitor its MVLS and may, if appropriate, consider implementing available options to regain compliance with the minimum MVLS rule.
• The company will continue to evaluate and may pursue a variety of capital raising options on an on-going basis.

Key Dates

Keywords

Dare Bioscience, women's health, Ovaprene, Sildenafil Cream, XACIATO, clinical trials, royalty sale, biopharmaceutical, FDA approval, contraception, sexual health, ARPA-H, Bill & Melinda Gates Foundation, equity financing